Ann: Company Update and Request for Extension of Suspension, page-133

First 133 Last

Share
Profile

Follow
workingdog

1,660 Posts.

259

30/03/23

05:48

Post #: 67033732
Share

Originally posted by Christopher67: ↑

Maybe their other venture is taking up too much time?

Mars mines has a flashy new website,, google it. I am surprised to see they don't have any Bauxite,,, do they know we have a world class bauxite tenement we can sell them ? CASH up front though. . . .

So far we have,
No Canntab sales.

Fusspot new products mentioned by Neil how many moons ago, still have never appeared. Milky mist and Double Duty Post #:63063007 on 11th August 2022. https://www.trendhunter.com/trends/fuss-pot the 2 new products mentioned here in July 2022.
Anyone seen them yet?
https://www.cosmeticsdesign-europe.com/Article/2022/07/06/cbd-hemp-skin-care-brand-fuss-pot-launches-in-france-and-eyes-european-expansion
France expansion mentioned in July 2022.
The 50% off sales that started for Black Friday last year, are still running.

Grassroots seems to have been a dud, their march competition had 1 entry on Facebook, and 4 on Instagram.
Free shipping on ALL orders. Still never got much traction with followers.

Costco - 1 pallet of hempseed oil capsules, and never again?

WSU clinical trial,, surely that would have started by now? We are coming up on 2 years since they announced WSU was designing the clinical trial protocol. https://newswire.iguana2.com/af5f4d73c1a54a33/cgb.asx/6A1027365/CGB_WESTERN_SYDNEY_UNIVERSITY_TO_UNDERTAKE_CLINICAL_TRIALS

Lots of work here to be done, maybe for $312,000 a year we could get a full time CEO based in Australia?

Expand

"Streamline our business"? CBD isolate is the main product - I like fuss pot and grassroots and hope they stick around but why bother (marion stepping down as well) if they are unprofitable and too much hassle compared to your core product.

Last edited by workingdog: 30/03/23

CGB Price at posting: 2.1¢ Sentiment: None Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 12 more messages in this thread...

First 133 Last

Add CGB (ASX) to my watchlist

Ann: Company Update and Request for Extension of Suspension, page-133

Top Stories

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News